We are live on ! Find out more
GRTX

Galera Therapeutics, Inc. Common Stock
GRTX

Delisted

GRTX was delisted on the 3rd of June, 2024.

Back to rankings
 

About: Galera Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. The Firm's lead product candidate, avasopasem manganese, is a highly selective small molecule dismutase mimetic for severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients with lung cancer, and the reduction of cisplatin-induced kidney damage in patients with cancer. The Firm's second product candidate, rucosopasem manganese, has been in development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC).

Employees: 7

Healthcare Drug Manufacturers - General

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 0%
Negative 0%
Neutral
GlobeNewsWire
2 years ago
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the first quarter ended March 31, 2024, and provided recent corporate updates.
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
Neutral
GlobeNewsWire
2 years ago
Galera Adopts Limited Duration Stockholder Rights Agreement
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors (the “Board”) has unanimously resolved to adopt a limited duration stockholder rights agreement (the “Rights Agreement”) to protect stockholder interests.
Galera Adopts Limited Duration Stockholder Rights Agreement
Neutral
GlobeNewsWire
2 years ago
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
Company continues to evaluate strategic options to maximize shareholder value Company continues to evaluate strategic options to maximize shareholder value
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
Neutral
GlobeNewsWire
2 years ago
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating potential strategic options to optimize shareholder value MALVERN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the third quarter ended September 30, 2023 and provided recent corporate updates.
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
See News Rankings
Price charts implemented using Lightweight Charts™